Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rescue Treatment With Rituximab-CHOP Therapy and Alemtuzumab (R-CHOP-A) in Refractory or Recidivant Patients With Chronic Lymphocytic Leukemia After Purine-analogous Treatment

NCT00504491 is registered in ClinicalTrials.gov with CABYC as lead sponsor.

NCT NCT00504491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rescue Treatment With Rituximab-CHOP Therapy and Alemtuzumab (R-CHOP-A) in Refractory or Recidivant Patients With Chronic Lymphocytic Leukemia After Purine-analogous Treatment
Lead sponsor
CABYC
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2007
Completion date
June 30, 2012
Enrollment
0 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, patients relapsed with purines therapy, patients resistant to a purine analogous